Jonathan Edwards
Senior Member (Voting Rights)
I think the key information we are missing is the placebo response rate.
The 30% response rate suggested in the ritux arm is also meaningless until we know placebo response rate. If that is also 30% then...
I am afraid Sasha is right on this. The trial is negative (I have had information via F&M). That means that the number of improvers was the same in both groups. The only legitimate conclusion is that there were no 'responders'. We have to assume that the apparent response at 6 months in phase 2 was a chance event.
Having watched events unfold over the last 3 years I had put the chance of a positive result from this trial at 40%. The jigsaw pieces were not fitting into place covincingly. It is a great credit to F &M that they did the critical trial. They have pursued this with spotless rigour and shown the way to the ME research community. But I do not think there is any reason to do further rituximab trials in ME. We need to follow other leads.